Literature DB >> 30008870

Effect of cytokine-induced killer cells combined with dendritic cells on the survival rate and expression of 14-3-3ζ and p-Bad proteins in Lewis lung cancer cell lines.

Yang Hou1, Dongyu Zang2, Xiaoming Li3, Fuzhi Li2.   

Abstract

In the present study, the function and mechanism of cytokine-induced killer cells (CIK) combined with dendritic cells (DC-CIK) were examined in Lewis lung cancer (LLC) cells. Co-culture of CIK dendritic cells (DC) in vitro was used to investigate their proliferation and the antitumor effects on LLC cells. DC and CIK cells were collected from healthy human peripheral blood mononuclear cells and co-cultured as an experimental group, while LLC cells were cultured alone as a control group. Cell morphology was observed by an inverted microscope and an MTT assay was utilized to detect the proliferation of LLC cells. Expression of 14-3-3ζ and p-Bad were measured by western blot analysis. Compared with the control group, treatment of LLC cells with DC-CIK resulted in decreased cell adherence, reduced cell proliferation and abnormal morphological changes. Additionally, DC-CIK treatment of LLC cells resulted in the decreased expression of 14-3-3ζ and p-Bad protein in LLC cells, which may provide important information pertaining to the possible mechanism of DC-CIK-induced antitumor activity against LLC cells. The present study provides a theoretical and experimental basis for the clinical treatment of DC-CIK cell co-culture.

Entities:  

Keywords:  Lewis lung cancer cell; cytokine-induced killer cells; dendritic cells; phosphorylated-Bad

Year:  2018        PMID: 30008870      PMCID: PMC6036427          DOI: 10.3892/ol.2018.8834

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  35 in total

1.  Knockdown of RhoGDIα induces apoptosis and increases lung cancer cell chemosensitivity to paclitaxel.

Authors:  F Rong; W Li; K Chen; D M Li; W M Duan; Y Z Feng; F Li; X W Zhou; S J Fan; Y Liu; M Tao
Journal:  Neoplasma       Date:  2012       Impact factor: 2.575

2.  Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial.

Authors:  Wei-Chen Lee; Hui-Chuan Wang; Chien-Fu Hung; Pei-Fang Huang; Chen-Rong Lia; Miin-Fu Chen
Journal:  J Immunother       Date:  2005 Sep-Oct       Impact factor: 4.456

3.  Dendritic cell immunotherapy combined with cytokine-induced killer cells promotes skewing toward Th2 cytokine profile in patients with metastatic non-small cell lung cancer.

Authors:  Peng Zhao; Xiaocui Bu; Xiaofang Wei; Weihong Sun; Xihe Xie; Changyou Li; Qingming Guo; Danni Zhu; Xiaoqiang Wei; Daiqing Gao
Journal:  Int Immunopharmacol       Date:  2015-02-16       Impact factor: 4.932

Review 4.  How I do it: radiofrequency ablation and cryoablation of lung tumors.

Authors:  Amita Sharma; William H Moore; Michael Lanuti; Jo-Anne O Shepard
Journal:  J Thorac Imaging       Date:  2011-05       Impact factor: 3.000

Review 5.  The future of cancer vaccines for non-small-cell lung cancer: ongoing trials.

Authors:  Aniruddha Choudhury; Marzia Palma; Håkan Mellstedt
Journal:  Clin Lung Cancer       Date:  2008-02       Impact factor: 4.785

6.  Immunohistochemical analysis of phospho-BAD protein and mutational analysis of BAD gene in gastric carcinomas.

Authors:  Eun Goo Jeong; Sung Hak Lee; Sung Soo Kim; Chang Hyeok Ahn; Nam Jin Yoo; Sug Hyung Lee
Journal:  APMIS       Date:  2007-08       Impact factor: 3.205

7.  Astaxanthin inhibits NF-κB and Wnt/β-catenin signaling pathways via inactivation of Erk/MAPK and PI3K/Akt to induce intrinsic apoptosis in a hamster model of oral cancer.

Authors:  K Kavitha; J Kowshik; T Kranthi Kiran Kishore; Abdul Basit Baba; S Nagini
Journal:  Biochim Biophys Acta       Date:  2013-05-29

Review 8.  Immunotherapy in the treatment of non-small cell lung cancer.

Authors:  Raghav Sundar; Richie Soong; Byoung-Chul Cho; Julie R Brahmer; Ross A Soo
Journal:  Lung Cancer       Date:  2014-05-14       Impact factor: 5.705

9.  A clinical study evaluating dendritic and cytokine-induced killer cells combined with concurrent radiochemotherapy for stage IIIB non-small cell lung cancer.

Authors:  X P Zhu; Y H Xu; J Zhou; X F Pan
Journal:  Genet Mol Res       Date:  2015-08-28

10.  Immune response, clinical outcome and safety of dendritic cell vaccine in combination with cytokine-induced killer cell therapy in cancer patients.

Authors:  Yu Cui; Xuejing Yang; Wei Zhu; Jiali Li; Xiaojing Wu; Yan Pang
Journal:  Oncol Lett       Date:  2013-06-04       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.